Twelve-Month Real-World Use of an Advanced Hybrid Closed-Loop System Versus Previous Therapy in a Dutch Center For Specialized Type 1 Diabetes Care
Authors' conclusion
Use of MM780G system results in significant and sustained glycemic improvements, consistent across age groups and irrespective of previous treatment modalities.
Study context
- Population
- Persons with T1D switching to the MM780G system at the Diabeter clinic (Dutch specialized T1D centre)334 with longitudinal data
- Participants
- 481 persons
- Exposure
- MM780G advanced hybrid closed-loop (aHCL) system vs previous therapy
- Previous therapyn = 219reference
- Outcome
- HbA1c
- Follow-up
- 12 months after MM780G initiation
Methodological detailssingle-centre, before-after comparison, age-stratified
- Single-centre
- Before-after comparison
- Age-stratified
Main finding
As reported in the abstract
P < 0.0001
Observational data: associations, not effects.
Further findings
PWDs with HbA1c <7%
GMI and TIR with MM780G · over 12 months
- GMI and TIR remained stable; mean GMI
- 6.9%
- TIR
- >70%
Age-stratified glycaemic control
- Consistent improvements across all age groups, with older participants achieving better outcomes
Recommended system settings
- Better glycaemic outcomes with recommended settings; TIR up to
- 77%
- TTIR up to
- 55%
Original publication
Twelve-Month Real-World Use of an Advanced Hybrid Closed-Loop System Versus Previous Therapy in a Dutch Center For Specialized Type 1 Diabetes Care. J Diabetes Sci Technol. Published 28 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →